Modern Hormone Therapy Shows No Increased Heart Risk in Large Study
A long-term analysis of over 52,000 Israeli women aged 45 to 59 found no significant link between contemporary hormone replacement therapy and higher risks of heart attack, stroke, blood clots, or death. The findings challenge earlier concerns tied to older HRT formulations and support current guidelines recommending early initiation of treatment. Regulatory updates, including the removal of black box warnings by the FDA, align with this emerging evidence.
A large-scale observational study of over 52,000 Israeli women aged 45 to 59, conducted by researchers at Clalit Health Services and Sapir College, found no significant increase in heart attack, stroke, blood clot, or premature death among those using contemporary hormone replacement therapy (HRT) compared to non-users after an average of 12 years of follow-up. The study, set to be presented at the American Heart Association’s Scientific Sessions 2026 in Chicago, analyzed data from women with no prior history of cardiovascular disease, cancer, or blood clots. Key findings showed nearly identical rates across groups: 4.4% of HRT users vs. 4.6% of non-users experienced a major cardiovascular event; death before age 80 occurred in 1.3% and 1.2%, respectively; and blood clot incidence was virtually identical at 0.33%. These results held across oral, patch, and gel formulations, suggesting consistency regardless of delivery method. The findings align with the FDA’s November 2025 decision to remove black box warnings from HRT products following a comprehensive review of modern data, signaling a shift in regulatory stance based on current formulations and usage patterns.
The background to this study lies in earlier concerns from randomized trials like the Women’s Health Initiative (WHI), which linked older HRT formulations—often high-dose estrogen-progestin combinations—to increased cardiovascular risk, especially when initiated years after menopause. These findings led to widespre
This study could significantly reshape how women and healthcare providers approach menopause management, potentially increasing HRT uptake among perimenopausal and early postmenopausal women who previously avoided it due to cardiovascular fears. With the FDA’s removal of black box warnings and growing evidence supporting safety when initiated early, patients may feel more empowered to pursue symptom relief without undue anxiety about heart disease. This shift could reduce long-term disability from severe menopause symptoms—such as sleep disruption, mood disorders, and sexual dysfunction—improving quality of life and workplace productivity. Institutions like the American Heart Association may further refine their guidance, reinforcing that HRT is not inherently cardiotoxic when used appropriately. A comparable precedent is the re-evaluation of statin use in primary prevention, where initial concerns over side effects were tempered by long-term data showing net benefit for at-risk popul